Pomalyst, Imnovid, Pomalidomide Celgene (pomalidomide) is a small molecule pharmaceutical. Pomalidomide was first approved as Pomalyst on 2013-02-08. It is used to treat kaposi sarcoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon. Pomalyst's patents are valid until 2031-06-21 (FDA).
|Trade Name||Imnovid, Pomalidomide Celgene|
|Indication||kaposi sarcoma, multiple myeloma|
|Drug Class||Thalidomide derivatives|